Thymus Extract and hepatitis

What 2 graded rows on thymus extract agree on for hepatitis, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Thymus Extract page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Thymus Extract page, with its PubMed record.

Supplement

Thymus Extract Choose another

2 rows · 82 people

Split. 1 row found no difference and 1 had mixed results.

No difference or mixed

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside. Outlined: mixed results.

From the rows

The best-graded row, grade D, is a randomized trial of 50 people (1985) and reported mixed results.

The rows run from 32 to 50 people, published from 1985 to 1998: 2 single studies.

1 no difference · 1 mixed

Grade DHepatitis C virus levels · No difference
RCT · n 32 · 1998 · Adults with chronic hepatitis C who had not responded to or could not tolerate interferon (US tertiary centre)
Label dose of the commercial product (not stated in the abstract) · 3 months vs placebo, then up to 6 months
Viral RNA levels at 3 months did not differ from placebo (3.48 vs 4.06 million copies/mL, P>0.2). All 19 people who completed 6 months stayed virus-positive, with levels similar to baseline.
Row on the Thymus Extract page · PubMed 9841585 (opens PubMed)
Grade DLiver enzymes and HBsAg clearance in acute hepatitis B · Mixed
RCT · n 50 · 1985 · Inpatients with acute hepatitis B
1 ampoule twice daily vs placebo · 30 days
AST, ALT and HBsAg clearance trended faster, but only the ALT decrease differed significantly from placebo.
Row on the Thymus Extract page · PubMed 3916838 (opens PubMed)